TIGIT and neoplasm: We constructed tumour models by injecting C57BL6 mice with WT (wild-type) U14, U14-NC-CD155 or U14-KO-CD155 cells to further verify the antitumor effects of targeting TIGIT/CD155 signalling in vivo.